US Supreme Court unanimously overturns Federal Circuit decision in Medtronic

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

US Supreme Court unanimously overturns Federal Circuit decision in Medtronic

The US Supreme Court has unanimously reversed the Federal Circuit decision in Medtronic v Boston Scientific, reinforcing the established rule that the patent owner bears the burden of proving that infringement has occurred

The ruling overturns a September 2012 decision by the Federal Circuit, which found that in cases where a licensee seeks a declaratory judgment against a patent holder, the licensee bears the burden of proof. The Federal Circuit reasoned that since Medtronic was asking a court to declare the products in question did not infringe, it should bear the burden of proving it was entitled to such relief.

But after hearing arguments in November last year, the Supreme Court unanimously ruled today that even in such cases, the patentee bears the burden of proof.

In its opinion, the Supreme Court quoted a decision in Precision Instrument Manufacturing v Automotive Maintenance Machin­ery: The public interest, of course, favours the maintenance of a well-functioning patent system. But the ‘public’ also has a ‘paramount interest in seeing that patent monopo­lies . . . are kept within their legitimate scope.'”

Justice Stephen Breyer, writing on behalf of all the justices, concluded: “The general public interest considerations are, at most, in balance. They do not favour a change in the ordinary rule imposing the burden of proving infringement upon the patentee.”

The dispute stems from 2007 claim that a device manufactured by Medtronic, known as a cardiac resynchronisation therapy, infringed patents owned by Mirowski Family Ventures, which licensed them to Boston Scientific. The parties had agreed that Medtronic would sub-license the patents and pay royalties on any new products it made which used the technology they covered.

But the parties disagreed on whether Medtronic’s CRT products used technology covered by the patents. The District Court for the District of Delaware found that the patents were valid and enforceable but that Medtronic did not violate them.

more from across site and SHARED ros bottom lb

More from across our site

AG Barr acquires drinks makers Fentimans and Frobishers, in deals worth more than £50m in total
Tarun Khurana at Khurana & Khurana says corporates must take the lead if patent filing activity is to truly translate into innovation
Michael Moore, head of legal at Glean AI, discusses how in-house IP teams can use AI while protecting enforceability
Counsel for SEP owners and implementers are keeping an eye on the case, which could help shape patent enforcement strategy for years to come
Jacob Schroeder explains how he and his team secured victory for Promptu in a long-running patent infringement battle with Comcast
After Matthew McConaughey registered trademarks to protect his voice and likeness against AI use, lawyers at Skadden explore the options available for celebrities keen to protect their image
The Via members, represented by Licks Attorneys, target the Chinese company and three local outfits, adding to Brazil’s emergence as a key SEP litigation venue
The firm, which has revealed profits of £990,837, claims it is the disruptive force in the IP-legal industry
In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of clinical trial protocols occurs before the application's filing date
Arun Hill at Clarivate assesses the Top 100 Global Innovators 2026 list, including why AI has assumed a strategic importance for innovation
Gift this article